Most material SEC filings — July 7, 2026

Semnur Pharmaceuticals announced a binding term sheet with iHolding Group LLP for a $100 million strategic investment. iHolding will purchase approximately 10 million newly issued shares at $10.00 per share. The investment is contingent on due diligence, definitive agreements, board approvals, and regulatory approvals; funds will support Phase 3 trials for SEMDEXA (SP-102), product development, and general corporate purposes.

CDT Equity Inc. (market cap ~$55K) issued a $1,971,000 original principal amount senior secured convertible note to J.J. Astor Co. on June 11, 2026 (amended June 30, 2026). The note carries a 1.35x factor rate, funds in two tranches ($268K initially, $1.13M on June 30), and requires 24 weekly installment payments of $82,125 through December 18, 2026. The lender receives a warrant for 912,500 shares (45% of $1.46M loan ÷ $0.72 closing price) and conversion rights at 90% of VWAP (10-day) or Nasdaq floor price, with 19.99% ownership cap. 80% of ATM financing proceeds flow to the lender until repaid; default triggers 120% principal increase and 19% annual interest.

House of Doge Inc. completed its merger with Brag House Holdings, Inc. on June 30, 2026, with the combined company retaining the House of Doge name and trading under ticker HODO on Nasdaq starting July 1, 2026. The merger involved Amendment No. 5 to the merger agreement (dated June 15, 2026), which restructured share consideration for major stockholders (Parker Haven Strategic Investments LP, Much Gains Investments LP, 1000516271 Ontario Inc., and Ryan Deslippe) into a mix of common stock (capped at 4.99% per holder) and Class C Preferred Stock. Post-closing, the company has approximately 75.9 million shares outstanding and CEO Marco Margiotta continues to lead the combined entity.

Polar Power, Inc. issued a $275,000 convertible promissory note (with $250,000 consideration and 10% original issue discount) to Mayers Ventures LLC, dated June 30, 2026, maturing December 30, 2027. The note bears 10% annual PIK interest, converts to common stock at 90% of 7-day VWAP (floor price: 20% of closing price prior to funding), includes a 130% mandatory default amount on default, and grants the holder a board seat and registration rights. The holder can exchange the note for Series A Preferred Stock at a 110% ratio or prepay at 115% of principal.

DevvStream Corp. entered into a Securities Purchase Agreement dated June 30, 2026, with EEME Energy SPV I LLC and Southern Energy Renewables Inc. EEME agreed to advance $5,000,000 in cash for 50,000 Series A Non-Voting Preferred Shares of DevvStream (non-convertible, senior in liquidation) and purchase $1,000,000 of DevvStream common shares at $0.28683 per share (3,486,386 shares). DevvStream simultaneously agreed to invest $5,000,000 in Southern Energy Renewables' Series A Preferred Shares. A $1,500,000 deposit was already advanced prior to the agreement date. The transaction is conditional on the Business Combination Agreement with XCF Global, and closing is by September 30, 2026.

Envirotech Vehicles closed its merger with Azio AI on July 2, 2026, issuing 2,655,157 shares of common stock and 973,450 shares of convertible preferred stock (convertible 100:1) to acquire 100% of Azio AI. The combined company has deployed 6 MW of off-grid power in South Texas and secured rights to a 548-acre site capable of supporting 500 MW capacity. Leadership changed: Chris Young appointed CEO/Chairman, Simon Yu appointed President, Jason Maddox became CFO, and Phillip Oldridge departed as former CEO.

On June 30, 2026, StageWise Strategies Corp. issued 1,000,000 common shares at $0.001 par value to Jakhongir Abidovich Artikkhodjaev for $250,000 in cash. Artikkhodjaev held ~75% of outstanding shares pre-issuance and is now diluted by the new issuance. The shares are restricted securities with transfer limitations pending registration or exemption under securities law.

On June 30, 2026, Interactive Strength Inc. issued 225,681 Series C Preferred Shares (at $2.00 original issue price) to Vertical Investors, LLC to settle a $451,361 liability owed under a Loss Restoration Agreement dated April 24, 2024. Vertical also agreed to repay amounts drawn on a letter of credit and cancel remaining availability. The settlement extinguishes Vertical's prior claims and grants Vertical consent rights over future indebtedness and preferred issuances senior to Series C.

Michael Buhle terminated as CEO effective June 17, 2026. Receives $200,000 severance (6 months base salary, paid in installments through 12/2026), 6 months COBRA coverage, and accelerated vesting of 64,583 stock options at $0.07/share exercise price. Of his 375,000 granted options, 35,417 were vested at separation; remaining 339,583 forfeit. Newly vested options subject to 90-day lock-up, $0.45 price floor, 2,500 daily share limit, and broker approval.

Z Squared Inc. filed an automatic shelf registration statement (Form S-3, File No. 333-297288) on July 7, 2026, effective immediately, authorizing up to $300,000,000 in at-the-market (ATM) offerings of common stock. The company entered into a Sales Agreement dated July 6, 2026 with Roth Capital Partners, LLC as the sole agent. The offering allows Z Squared to issue shares opportunistically over time at prevailing market prices.

Banzai International (market cap ~$12.1M) agreed to acquire ConnectAndSell's AI sales platform business for: (i) $750k cash + 294,917 shares (~$5.9M) + 1,685,175 pre-funded warrants + $1.8M promissory note at Closing; (ii) $1.5M deferred payment within 30 days; (iii) $3.25M deferred payment by Dec 31, 2026; (iv) up to $2M earn-out based on revenue targets. Total upfront consideration ~$8.45M; total deal value ~$15.2M (excluding earnout). Transaction valued at ~126% of Buyer's current market cap.

DigitalOcean reports record Q2 2026 results with remaining performance obligations (RPO) expected to exceed $800M, up >10X from Q2 2025 (~$80M implied), driven by multiple nine-figure annual customer commitments for AI inference products. Revenue growth accelerates to 29% YoY (vs. 14% in Q2 2025), weighted average RPO life extends to 3+ years from 1.6 years, and company secures 20 MW additional data center capacity for late 2027/early 2028, expanding total committed capacity to ~155 MW.

MacroGenics completed the sale of its GMP drug substance manufacturing operations and CDMO business to Bora Pharmaceuticals Co., Ltd. for $122.5 million in cash (before transaction fees), effective June 30, 2026. The transaction includes transfer of manufacturing facilities in Rockville, MD and warehouse in Frederick, MD, with approximately 140 MacroGenics employees hired by Bora. MacroGenics retains a supply agreement with Bora for its internal pipeline manufacturing needs and is eligible for up to $5 million in contingent consideration upon achievement of manufacturing milestones in 2027-2028.

On May 8, 2025 and October 24, 2025, Rise Gold issued warrants to related parties Daniel Oliver Jr. and Myrmikan Gold Fund, LLC under amended standstill agreements prohibiting warrant exercise for 61 days. May 8: Oliver received 304,800 warrants at $0.15/share; Myrmikan received 3,245,171 warrants at $0.15/share. October 24: Myrmikan received additional 1,000,000 warrants at $0.45/share. Total new warrants issued: ~4.55M shares. Standstill period allows only passive holding.

COMPASS Pathways reported positive Phase 3 data (COMP006, COMP005) for COMP360 psilocybin in treatment-resistant depression across >1,000 participants. COMP006 (N=581) met primary endpoint (p<0.001) with 25mg dose showing rapid onset (day 2) and durability through 26 weeks; 39% achieved clinically meaningful response at week 6. Safety profile favorable: 94.6% experienced adverse events but majority were transient and on treatment day only; serious adverse events low (5.7% in 25mg arm). Rolling NDA submission and FDA National Priority Voucher already granted; final submission expected Q4 2026; commercial launch targeted H1 2027 with ~578 treatment centers prepared. Market: 4M U.S. TRD patients and 13M PTSD patients identified.

Vivani Medical, Inc. (Seller) agreed to merge with ClearOne Inc. (Parent) via a forward merger of Parent's subsidiary into Cortigent, Inc. (Company). Seller, the sole owner of Company, will receive 12,500,000 shares of Parent Common Stock as consideration. Parent will simultaneously raise $10–15M (2.5–5M units at undisclosed pricing) via Financing, with each unit containing one common share and one warrant exercisable at $10/share for 6 months. The merger is structured as a tax-free reorganization under Section 368(a) of the Code. Seller's shares are subject to staggered lock-ups (50% for 1 year, 50% for 2 years). ThinkEquity LLC is financial advisor to Seller and Company.

Aptera Motors received its EPA Certificate of Conformity (CoC) on June 18, 2026, for the 2026 Launch Edition vehicle, confirming federal emissions compliance. This is one of two primary federal certifications required before U.S. vehicle sales; the company still must complete Federal Motor Vehicle Safety Standards (FMVSS) testing using its low-volume validation assembly line before customer deliveries can begin.

Microbot Medical reported greater than 100% revenue and customer growth in Q2 2026 (ended June 30) versus Q1 2026, following the April 13, 2026 Full Market Release of its LIBERTY Endovascular Robotic System. The company expanded sales territories from 4 to 8 in Q2 and plans to reach 12 by year-end 2026; entered into an agreement with Lovell Government Services to serve federal healthcare systems (VHA, MHS, IHS); received Israeli Ministry of Health marketing clearance; and established a second manufacturing site to support scaling.

Capstone Energy+ (formerly Capstone Green Energy Holdings) transitioned from OTC Markets (OTCQX: CGEH) to The Nasdaq Global Select Market under ticker symbol CEPL, effective July 8, 2026. The company cited strengthened financial foundation, simplified capital structure, and return to profitability over the past two years as justifications. No concrete financial metrics, deal amounts, or operational changes are detailed in the filing—it is a pure listing announcement.

BIO-key International (Nasdaq: BKYI, market cap ~$4.9M) announced on July 7, 2026 that Nasdaq approved reinstatement of its common stock trading effective July 8, 2026, following a June 16 hearing panel determination that the company regained compliance with continued listing standards including minimum bid price and SEC filing requirements. The company remains subject to a Discretionary Panel Monitor for one year (until July 6, 2027). No financial metrics, share count changes, or specific remediation actions are detailed in the filing.

On June 30, 2026, Glimpse Group sold its wholly-owned subsidiary Glimpse Learning LLC to Glimpse Learning Inc (a newly formed Wyoming company). Buyer issued Glimpse Group 1,999,999 shares (19.99% equity stake). Consideration also includes: (1) NIH payment of $58,000 if/when NIH invoice of $167,963 is collected by Sept 30, 2026; (2) $18,000 payments on Dec 1, 2026 and Mar 1, 2027; (3) royalties of 7% of revenue July 1, 2027–Dec 31, 2027, then 10% thereafter, capped at $1.2M total, with buyout option at $1M on Dec 30, 2027; (4) Buyer assumed liabilities and paid $200,000 working capital adjustment. Sale eliminates ~$890K of the company's ~$3.4M nine-month revenue (26% of top line) and ~$1.2M of ~$1.9M operating losses.

bioAffinity Technologies reported Q2 2026 CyPath Lung sales growth >200% year-over-year and 30% sequentially, with 155% increase in physician offices ordering the test versus Q2 2025. The company has now performed nearly 3,000 tests total since commercial launch, with expanding adoption across pulmonology practices, lung nodule clinics, academic centers, and VA facilities. No specific revenue dollar amounts, test pricing, or customer count are disclosed.

CAMAC Fund, LP (managed by Eric Shahinian via Camac Capital, LLC) purchased 82,542 shares of Cryo-Cell International common stock between May 11 and July 6, 2026, at prices ranging from $3.115 to $3.450 per share. A single transaction on July 2, 2026 accounted for 47,046 shares at $3.299. This represents a material accumulation by an activist/significant shareholder filing under Schedule 13D.

Penguin Solutions reported Q3 FY2026 net sales of $479M (up 48% YoY), GAAP diluted EPS of $0.68 vs. $(0.01) prior year, and Non-GAAP diluted EPS of $0.84 (up 79% YoY). The company raised full-year FY2026 guidance: net sales growth now expected at 22% ±2% (vs. prior 12% ±5%), GAAP EPS to $1.97 ±$0.05 (vs. prior $1.30 ±$0.15), and Non-GAAP EPS to $2.60 ±$0.05 (vs. prior $2.15 ±$0.15). Integrated Memory net sales more than doubled YoY to $275M; AI Infrastructure added four new customer logos in Q3. No specific counterparty names or material M&A disclosed.

VSee Health issued two convertible promissory notes totaling $507,000 in principal ($250K net from ClearThink Capital Partners, LLC dated June 17, 2026; $257K net from Vanquish Funding Group Inc. dated June 18, 2026). Both notes convert to common stock at 85% and 75% of 10-day VWAP respectively, with maturity in 12 months, monthly payments, 10-22% interest, and 120-150% default multipliers. As of June 2026, company had 47.3–48.6M shares outstanding (100M authorized). Placement agent Spartan Capital received $25K; legal/due diligence fees of $12K reimbursed to lenders.

On July 2, 2026, Lakeside Holding Limited filed amended articles of incorporation approved by stockholders (81.86% vote) on February 12, 2026. The company added authorization for 1,000,000,000 shares of blank-check preferred stock ($0.0001 par) with full board discretion over dividends, voting rights, conversion, redemption, and liquidation preferences. Common stock authorization remains 2,000,000,000 shares. The amendment also lowered voting threshold for future share authorization changes to 50% majority (single class vote), removing class-level veto rights.

21Shares Dogecoin ETF (total assets ~$1.9M) filed an 8-K on 2026-07-07 reporting termination of a material definitive agreement effective 2026-06-30. The filing does not disclose the counterparty identity, dollar amounts, specific terms, or reasons for termination—only that Item 1.02 was triggered, indicating a material agreement was ended.

Children's Place, Inc. issued a $15M unsecured subordinated promissory note to Mithaq Capital SPC on July 1, 2026. The note carries interest at Term SOFR + 9.00%, matures April 16, 2031, and is subordinated to $40M+ in senior indebtedness (ABL and Senior Secured Term Loan facilities). Simultaneously, Muhammad Asif Seemab was appointed President and Interim CEO at $497,500 annual salary, with a 12-month non-compete post-termination.

21Shares Solana ETF filed an 8-K on July 7, 2026, disclosing termination of a material definitive agreement as of June 30, 2026 (Item 1.02). The filing provides no specific details about the counterparty, dollar amounts, reasons for termination, or financial impact. With only $2.9M in total assets, any material agreement termination is potentially significant.

Corvex's board increased authorized Series D Non-Voting Convertible Preferred Stock from 30,227.0524 shares to 50,000 shares on July 1, 2026. The increase was authorized by board resolution and approved by majority vote of existing Series D holders. The filing discloses no pricing, conversion terms, or use of proceeds for this authorization.

Ault Lending, LLC purchased 64,000 shares between 06/24/2026–07/06/2026 at prices ranging from $1.21 to $1.71 per share (total ~$82,500). Alpha Structured Finance LP purchased 9,983 shares on 07/02/2026 at $1.2625 per share (total ~$12,600). Combined acquisition of 74,983 shares represents material increase in insider/affiliate holdings relative to company's $12.1M market cap.

10% owner Corbin Capital Partners, L.P. (NONE) bought 247K shares (~$2.5M) on the open market (6.6% of holdings). Open-market insider purchase — historically a bullish signal.

Coty agreed with Kering to terminate the Gucci Beauty license approximately one year early (ending June 30, 2027 vs. original term end). Coty receives ~$400M total consideration ($250M cash at signing July 2026, $150M by Sept 30, 2027, with up to $30M contingent). Coty will continue operating Gucci Beauty through transition, sell inventory to Kering, and use proceeds for debt reduction and reinvestment in core brands.

Evolution Metals Technologies Corp. (EMAT, market cap ~$7.1M) executed a supply agreement with Senri Trading Co., Ltd. to purchase bulk quantities of Neodymium-Praseodymium (NdPr) metal from SRE Vietnam, a subsidiary of Tokai Trading Co., Ltd. (Japan). The non-China sourced NdPr metal will support EMAT's expansion to ~10,000 metric tons per annum of rare earth magnet production capacity. No specific contract dollar amount, duration, or volume commitments are disclosed in the filing.

Treasurer CHAD EISENBERG (VFLEX) bought 54K shares (~$1.5M) on the open market (100% of holdings). Open-market insider purchase — historically a bullish signal.

President PECK MICHAEL D (VFLEX) bought 181K shares (~$5.0M) on the open market (100% of holdings). Open-market insider purchase — historically a bullish signal.

PRESIDENT PECK MICHAEL D (FTECX) bought 160K shares (~$1.5M) on the open market (100% of holdings). Open-market insider purchase — historically a bullish signal.

Tvardi announced Phase 1 results for TTI-109, a phosphate prodrug of its STAT3 inhibitor TTI-101. The study (three-part design, n=32 in MAD cohort) confirmed rapid conversion to TTI-101 within 2 hours at 95% efficiency, dose-proportional pharmacokinetics with exposures above STAT3 IC₅₀, and exploratory pharmacodynamic data showing up to 60% reductions in disease-relevant immune cell populations (Th17, Tfh, B cells). Critically, diarrhea duration with TTI-109 was substantially shorter (0.46 days) versus TTI-101 (3.35 days) at near-equivalent doses. Company plans Phase 2 trials in dermatologic and GI diseases, contingent on IND clearance and additional funding. Cash position: $25.0M; runway extends to Q4 2026.

Standard Nuclear, Inc. filed an amended S-1 registration statement for an IPO of 18,250,000 Class A shares priced at $18–$21 per share (midpoint $19.50), targeting $328–$383M gross proceeds. The company manufactures TRISO advanced nuclear fuel at Oak Ridge, Tennessee; expects operational facilities in Idaho and a joint venture with Framatome in Washington by late 2026; and reports $245M total contract backlog ($65M funded, $157M in purchase options, $23M contingent), plus $986M qualified pipeline. As of March 31, 2026, the company held $124.9M cash, a $79.9M accumulated deficit, and negative operating cash flow of $4.3M. Founder Thomas Hendrix will own ~59.5% voting power post-IPO (20-vote Class B shares).

As of July 3, 2026, Digi Power X held ~$155M in cash with zero long-term debt, having deployed ~$95M year-to-date into its Alabama data center campus entirely from internal resources. The company's flagship AI data center Phase 1 remains on track for December 2026 service, Phase 2 for Q1 2027, with all major long-lead equipment secured. NeoCloudz GPU-as-a-Service platform is live and generating AI revenues; FY2027 targets $250–300M annualized run rate across three segments: colocation ($80–200M), GPU-as-a-Service (~$100M), and energy sales (~$12M).

Turn Therapeutics completed a comprehensive interim analysis of its adaptive Phase 2 trial of GX-03 in atopic dermatitis (AD). The trial enrolled ~50 patients in Stage 1. Interim data showed clinically meaningful efficacy across a broader disease-severity spectrum than originally anticipated, including patients with mild-to-moderate AD (baseline EASI 1.1–7.0). The optimized Stage 2 design will now prospectively enroll ~120–135 patients stratified across the full EASI spectrum (1.1–7.0, 7.1–15.9, ≥16), evaluate four prespecified endpoints using FDA-recognized Hochberg multiple-testing procedure, and complete enrollment by Q4 2026. No serious adverse events or discontinuations have been reported; safety profile remains favorable. The company states it remains sufficiently capitalized through Q3 2027.

Spanish regulatory authority AEMPS authorized Theriva to begin VIRAGE2, a Phase 2a proof-of-concept trial with 6 patients evaluating more frequent dosing (≥3 doses, 2 months apart) of VCN-01 combined with standard-of-care chemotherapy in metastatic pancreatic cancer. The trial builds on positive VIRAGE Phase 2b results (112 patients) showing 2 doses of VCN-01 improved overall survival, progression-free survival, and duration of response versus single-dose or chemotherapy alone. Results will inform dosing for a potential future Phase 3 trial.

Axos Financial announced a definitive agreement to acquire Arc Technologies, Inc., a financial technology platform founded in 2021 serving technology and growth companies. Arc provides integrated cash management, capital markets, and AI-powered financial software solutions. The transaction is expected to close in July 2026, subject to customary closing conditions. No purchase price, stock consideration, or specific financial terms are disclosed in this filing.

Thomas J. McInerney, President and CEO of Genworth Financial since January 2013, is taking a temporary leave of absence to focus on his health. Jerome Upton, CFO since March 2023 and a company veteran since 1998, has been named Interim President and CEO effective immediately. The Board stated confidence in continuity and execution of existing strategy during the interim period.

CareDx completed sale of Lab Products business (IVD PCR/NGS kits) to Eurobio Scientific for $171.2M cash on June 30, 2026, and completed acquisition of Naveris (NavDx HPV-cancer MRD test generating ~$35M 2025 revenue) in Q3 2026. Together, these transactions pivot the company from global diagnostics toward U.S. precision medicine in transplant and specialty oncology, expanding addressable market to >$12B.

Conexeu Sciences completed its 12-month P.R.O.O.F preclinical study of its CXU™ platform, demonstrating tissue restoration in small and large-volume facial models and meeting injectable performance benchmarks (injectability and volumizing). The company plans a predicate-based 510(k) submission for wound care in Q1 2027, targeting a 90-day FDA review, with subsequent expansion into the $11 billion medical aesthetics market; results will be submitted for peer-reviewed publication but detailed quantitative data were not disclosed.

Figure Technology Solutions reported preliminary June 2026 operating data exceeding prior guidance. Consumer Loan Marketplace Volume reached $4,259M in Q2 2026 (up 47% Q/Q, up 132% Y/Y from $1,838M in Q2 2025). $YLDS in circulation stood at $556M; Democratized Prime matched offers balance was $392M; borrower demand $414M; available lender supply $522M. The company launched a weekly operational dashboard for near-real-time transparency. All figures are unaudited preliminary estimates subject to change upon financial closing.